STAT3, but not Ki-67, expression is independently associated with tumor progression in colorectal carcinoma: A comparative immunohistochemical biomarker analysis
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
I Gede Putu Adhi Wedharga
https://orcid.org/0009-0006-2853-8752
Vincentius Michael Willianto
https://orcid.org/0000-0002-4917-4971
Imelda Theodora
https://orcid.org/0000-0003-2453-8203
Irene Parengkuan
https://orcid.org/0000-0002-7407-9052
Bernadette Dian Novita
https://orcid.org/0000-0001-5624-7043
Abstract
The insidious progression of colorectal carcinoma (CRC) at early stages often hampers timely screening and diagnosis, resulting in delayed intervention and poor clinical outcomes. Ki-67 and Signal Transducer and Activator of Transcription 3 (STAT3) have been widely studied for their roles in tumor proliferation and survival. However, comparative studies assessing their clinicopathological relevance in CRC progression remain limited, and their relative contributions to tumor aggressiveness are unclear. This study aimed to evaluate the clinicopathological significance and association of Ki-67 and STAT3 expression with tumor aggressiveness, focusing on their roles in tumor infiltration and size as indicators of CRC progression. Thirty-eight formalin-fixed, paraffin-embedded (FFPE) CRC tissue specimens were collected from patients undergoing surgical resection for this cross-sectional study. Ki-67 and STAT3 expression were assessed using immunohistochemical (IHC) staining. Clinicopathological data were retrieved from medical records. Protein expression was quantified using inverted mean gray values via digital image analysis. Ki-67 and STAT3 expression levels significantly correlated with tumor infiltration (Ki-67: r = 0.322, p = 0.049; STAT3: r = 0.429, p = 0.007) and size (Ki-67: r = 0.425, p = 0.008; STAT3: r = 0.452, p = 0.004). No significant correlation was found between Ki-67 and STAT3 (r = 0.225, p = 0.175). Only STAT3 was independently associated with infiltration (OR per 1-standard deviation: 4.11, p = 0.043) and size (OR per 1-SD: 3.41, p = 0.047). While both markers are associated with CRC progression, only STAT3 shows an independent association with tumor aggressiveness, underscoring its role beyond cell proliferation and suggesting broader involvement in tumor invasion and progression pathways.
Downloads
##plugins.themes.bootstrap3.article.details##
Copyright (c) 2025 I Gede Putu Adhi Wedharga, Vincentius Michael Willianto, Imelda Theodora, Irene Parengkuan, Bernadette Dian Novita
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
References
Sharma R, Abbasi-Kangevari M, Abd-Rabu R, Abidi H, Abu-Gharbieh E, Acuna JM, et al. Global, regional, and national burden of colorectal cancer and its risk factors, 1990–2019: A systematic analysis for the global burden of disease study 2019. Lancet Gastroenterol Hepatol. 2022;7(7):627-647. https://doi.org/10.1016/S2468-1253(22)00044-9
Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol. 2021;14(10):101174. https://doi.org/10.1016/j.tranon.2021.101174
Hossain MS, Karuniawati H, Jairoun AA, Urbi Z, Ooi DJ, John A, et al. Colorectal cancer: A review of carcinogenesis, global epidemiology, current challenges, risk factors, preventive and treatment strategies. Cancers (Basel). 2022;14(7):1732. https://doi.org/10.3390/cancers14071732
Theodora I, Sudiana IK, Budipramana VS, Erwin F, Dewi S, Novita BD. Tumor differentiation is correlated with Estrogen Receptor Beta (ERβ) expression but not with Interleukin-6 (IL-6) expression in colorectal carcinoma. Indones Biomed J. 2024;16(5):481–6. https://doi.org/10.18585/inabj.v16i5.3324
Roshandel G, Ghasemi-Kebria F, Malekzadeh R. Colorectal cancer: Epidemiology, risk factors, and prevention. Cancers (Basel). 2024;16(8):1530. https://doi.org/10.3390/cancers16081530
Parmar S, Easwaran H. Genetic and epigenetic dependencies in colorectal cancer development. Gastroenterol Rep (Oxf). 2022:10:goac035.. https://doi.org/10.1093/gastro/goac035
Cortés-Ballinas L, López-Pérez TV, Rocha-Zavaleta L. STAT3 and the STAT3-regulated inhibitor of apoptosis protein survivin as potential therapeutic targets in colorectal cancer (Review). Biomed Rep. 2024;21(6):175. https://doi.org/10.3892/br.2024.1863
Lin H, Ho A, Huang H, Yang B, Shih B, Lin H, et al. STAT3‐mediated gene expression in colorectal cancer cells‐derived cancer stem‐like tumorspheres. Adv Dig Med. 2021;8(4):224–33. https://doi.org/10.1002/aid2.13223
Lișcu HD, Verga N, Atasiei DI, Badiu DC, Dumitru AV, Ultimescu F, et al. Biomarkers in colorectal cancer: Actual and future perspectives. Int J Mol Sci. 2024;25(21):11535. https://doi.org/10.3390/ijms252111535
Liu Q, Ran D, Wang L, Feng J, Deng W, Mei D, et al. Association between Ki67 expression and therapeutic outcome in colon cancer. Oncol Lett. 2023;25(6):272. https://doi.org/10.3892/ol.2023.13858
Uxa S, Castillo-Binder P, Kohler R, Stangner K, Müller GA, Engeland K. Ki-67 gene expression. Cell Death Differ. 2021;28(12):3357-3370. https://doi.org/10.1038/s41418-021-00823-x
Lei HT, Yan S, He YH, Xu N, Zhao M, Yu CJ, et al. Ki67 testing in the clinical management of patients with non metastatic colorectal cancer: Detecting the optimal cut off value based on the Restricted Cubic Spline model. Oncol Lett. 2022;24(6):420. https://doi.org/10.3892/ol.2022.13540
Spitzner M, Roesler B, Bielfeld C, Emons G, Gaedcke J, Wolff HA, et al. STAT3 inhibition sensitizes colorectal cancer to chemoradiotherapy in vitro and in vivo. Int J Cancer. 2014;134(4):997–1007. https://doi.org/10.1002/ijc.28429
Calu V, Ionescu A, Stanca L, Geicu OI, Iordache F, Pisoschi AM, et al. Key biomarkers within the colorectal cancer related inflammatory microenvironment. Sci Rep. 2021;11(1):7940. https://doi.org/10.1038/s41598-021-86941-5
Tjahjono Y, Caroline, Foe K, Wijaya H, Dewi BDN, Karnati S, et al. 2-(3-(Chloromethyl)benzoyloxy) benzoic Acid reduces prostaglandin E-2 concentration, NOX2 and NFKB expression, ROS production, and COX-2 expression in lipopolysaccharide-induced mice. Prostaglandins Other Lipid Mediat. 2024:174:106866. https://doi.org/10.1016/j.prostaglandins.2024.106866
Zhuang M, Ding X, Song W, Chen H, Guan H, Yu Y, et al. Correlation of IL-6 and JAK2-STAT3 signaling pathway with prognosis of nasopharyngeal carcinoma patients. Aging (Albany NY). 2021;13(12):16667-16683. https://doi.org/10.18632/aging.203186
Tong G, Zhang G, Liu J, Zheng Z, Chen Y, Niu P, et al. Cutoff of 25% for Ki67 expression is a good classification tool for prognosis in colorectal cancer in the AJCC 8 stratification. Oncol Rep. 2020;43(4):1187–98. https://doi.org/10.3892/or.2020.7511
Han C, Sun B, Zhao X, Zhang Y, Gu Q, Liu F, et al. Phosphorylation of STAT3 promotes vasculogenic mimicry by inducing epithelial-to-mesenchymal transition in colorectal cancer. Technol Cancer Res Treat. 2017;16(6):1209–1219. https://doi.org/10.1177/1533034617742312
Grund B, Sabin C. Analysis of biomarker data: Logs, odds ratios, and receiver operating characteristic curves. Curr Opin HIV AIDS. 2010;5(6):473–9. https://doi.org/10.1097/COH.0b013e32833ed742
Morikawa T, Baba Y, Yamauchi M, Kuchiba A, Nosho K, Shima K, et al. STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers. Clin Cancer Res. 2011;17(6):1452-62. https://doi.org/10.1158/1078-0432.CCR-10-2694
Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: A leading role for STAT3. Nat Rev Cancer. 2009;9(11):798-809. https://doi.org/10.1038/nrc2734
Rahadiani N, Habiburrahman M, Abdullah M, Jeo WS, Stephanie M, Handjari DR, et al. Analysing 11 years of incidence trends, clinicopathological characteristics, and forecasts of colorectal cancer in young and old patients: a retrospective cross-sectional study in an Indonesian national referral hospital. BMJ Open. 2022;12(9):e060839. https://doi.org/10.1136/bmjopen-2022-060839
Schmuck R, Gerken M, Teegen EM, Krebs I, Klinkhammer-Schalke M, Aigner F, et al. Gender comparison of clinical, histopathological, therapeutic and outcome factors in 185,967 colon cancer patients. Langenbecks Arch Surg. 2020;405(1):71-80. https://doi.org/10.1007/s00423-019-01850-6
Shaukat A, Kahi CJ, Burke CA, Rabeneck L, Sauer BG, Rex DK. ACG clinical guidelines: Colorectal cancer screening 2021. Am J Gastroenterol. 2021;116(3):458-479. https://doi.org/10.14309/ajg.0000000000001122
Crowe A, Yue W. Semi-quantitative determination of protein expression using immunohistochemistry staining and analysis: an integrated Protocol. Bio Protoc. 2019;9(24):e3465. https://doi.org/10.21769/bioprotoc.3465
Yang SF, Yuan SSF, Yeh YT. Positive association between STAT3 and Ki-67 in cervical intraepithelial neoplasia. Kaohsiung J Med Sci. 2006;22(11):539-46. https://doi.org/10.1016/S1607-551X(09)70350-X
Yang SF, Yuan SSF, Yeh YT, Wu MT, Su JH, Hung SC, et al. The role of p-STAT3 (ser727) revealed by its association with Ki-67 in cervical intraepithelial neoplasia. Gynecol Oncol. 2005;98(3):446–52. https://doi.org/10.1016/j.ygyno.2005.05.032
Wu L-J, Li H-X, Luo X-T, Lu R-Z, Ma Y-F, Wang R, et al. STAT3 activation in tumor cell-free lymph nodes predicts a poor prognosis for gastric cancer. Int J Clin Exp Pathol. 2014;7(3):1140–6. https://pmc.ncbi.nlm.nih.gov/articles/PMC3971319/
Koveitypour Z, Panahi F, Vakilian M, Peymani M, Seyed Forootan F, Nasr Esfahani MH, et al. Signaling pathways involved in colorectal cancer progression. Cell Biosci. 2019;97(9):1-14. https://doi.org/10.1186/s13578-019-0361-4
Zhang X, Hu F, Li G, Li G, Yang X, Liu L, et al. Human colorectal cancer-derived mesenchymal stem cells promote colorectal cancer progression through IL-6/JAK2/STAT3 signaling. Cell Death Dis. 2018;9(2):25. https://doi.org/10.1038/s41419-017-0176-3
Xiao L, Li X, Cao P, Fei W, Zhou H, Tang N, et al. Interleukin-6 mediated inflammasome activation promotes oral squamous cell carcinoma progression via JAK2/STAT3/Sox4/NLRP3 signaling pathway. J Exp Clin Cancer Res. 2022;41(1):166. https://doi.org/10.1186/s13046-022-02376-4
Andrés-Sánchez N, Fisher D, Krasinska L. Physiological functions and roles in cancer of the proliferation marker Ki-67. J Cell Sci. 2022;135(11): jcs258932. https://doi.org/10.1242/jcs.258932
Mrouj K, Andrés-Sánchez N, Dubra G, Singh P, Sobecki M, Chahar D, et al. Ki-67 regulates global gene expression and promotes sequential stages of carcinogenesis. Proc Natl Acad Sci U S A. 2021;118(10):e2026507118. https://doi.org/https://doi.org/10.1073/pnas.2026507118
Zhang G, Hou S, Li S, Wang Y, Cui W. Role of STAT3 in cancer cell epithelial-mesenchymal transition (Review). Int J Oncol. 2024;64(5):48. https://doi.org/10.3892/ijo.2024.5636
Rébé C, Ghiringhelli F. STAT3, a master regulator of anti-tumor immune response. Cancers (Basel). 2019;11(9):1280. https://doi.org/10.3390/cancers11091280
Su Z, El Hage M, Linnebacher M. Mutation patterns in colorectal cancer and their relationship with prognosis. Heliyon. 2024;10(17):e36550. https://doi.org/10.1016/j.heliyon.2024.e36550